Human artificial chromosome (HAC) vector with a conditional centromere for correction of genetic deficiencies in human cells Human artificial chromosome (HAC)-based vectors offer a promising system for delivery and expression of full-length human genes of any size. HACs avoid the limited cloning capacity, lack of copy number control, and insertional mutagenesis caused by integration into host chromosomes that plague viral vectors. We previously described a synthetic HAC that can be easily eliminated from cell populations by inactivation of its conditional kinetochore. Here, we demonstrate the utility of this HAC, which has a unique gene acceptor site, for delivery of full-length genes and correction of genetic deficiencies in human cells. A battery of functional tests was performed to demonstrate expression of NBS1 and VHL genes from the HAC at physiological levels. We also show that phenotypes arising from stable gene expression can be reversed when cells are "cured" of the HAC by inactivating its kinetochore in proliferating cell populations, a feature that provides a control for phenotypic changes attributed to expression of HAC-encoded genes. This generation of human artificial chromosomes should be suitable for studies of gene function and therapeutic applications.
gene delivery vector | gene therapy | transformation-associated recombination cloning M ost advanced current gene therapy systems, such as adenovirus-, lentivirus-, and retrovirus-derived vectors, use cDNA or "minigene" constructs (reviewed in refs. [1] [2] [3] [4] [5] that cannot recapitulate the physiological regulation of complex endogenous loci. Viral episomal vectors carrying HSV-1 and EBV amplicons can deliver and express full-length genes as large as approximately 150 kb in size (1, 2). However, several concerns limit the use of HSV-1 and EBV viral vectors: absence of strong copy number control, undesired immunological responses, and occasional integration into the host genome, causing insertional mutagenesis and gene silencing (6) .
Human artificial chromosomes (HACs) represent another extrachromosomal gene delivery and gene expression vector system (7) (8) (9) (10) (11) . Although this technology is less advanced than virusderived vectors, HACs have several potential advantages over currently used episomal viral vectors for gene therapy applications. First, the presence of a functional centromere provides long-term stable maintenance of HACs as single-copy episomes without integration to the host chromosomes. Second, there is no upper size limit to DNA cloned in a HAC: entire genomic loci with all regulatory elements can be used. Finally, HAC vectors minimize adverse host immunogenic responses and the risk of cellular transformation.
Recent advances have produced a variety of HACs via two different approaches. The "top-down" approach involves modification of human chromosomes in living cells to produce chromosome derivatives (11) (12) (13) (14) (15) (16) (17) (18) . The "bottom-up" approach involves de novo kinetochore assembly from 50-to 100-kb blocks of centromeric alpha-satellite (i.e., alphoid) DNAs. These are multimerized in human cells, forming HACs with sizes of approximately 1 to 3 Mb (7, 8, 10, 19) . Several groups have reported successful expression of full-length genes in HACs (9-11, 20, 21) . However, in most cases, genes to be expressed were cotransfected with an alphoid DNA array into human cells and were incorporated into the forming HAC in vivo. Therefore, gene copy number and location of the gene on the HAC were not predetermined. These factors greatly limited the application of de novo-generated HACs as gene delivery vectors.
Recently, this limitation was overcome by construction of an alphoid tetO -HAC carrying loxP sites (22, 23) . This circular HAC contains approximately 6,000 copies of the tetracycline operator (tetO) sequence embedded in a synthetic alphoid DNA array. Although the HAC is mitotically stable, tethering certain tetracycline repressor fusion proteins (tetR-KAP1 or tTS) (22, 24) inactivates the centromere, resulting in HAC loss. Thus, the alphoid tetO -HAC and any genes it carries can be eliminated from cell populations, allowing for a regulated "hit-and-run" induction of phenotypic changes.
To minimize problems caused by the lack of certain genes from libraries of BAC and YAC clones or the presence of genes fragmented on multiple vectors, we developed a method for direct gene cloning from genomic DNA. Transformation-associated recombination (TAR) cloning allows isolation of any specific allele of a gene of interest as a predetermined DNA fragment (25, 26) .
Here, we describe the combination of the TAR gene-cloning technology with the alphoid tetO -HAC vector for gene delivery. We report a complete cycle starting with selective gene isolation, followed by gene loading into the HAC, and eventually leading to complementation of gene deficiencies in a human cell line (Fig. 1 ). This approach is useful for studies of gene function and potentially for gene therapy. As a proof of principle, genomic copies of two average-size cancer-associated genes-VHL mutated in von Hippel-Lindau syndrome (VHL; MIM 193300) and NBS1 mutated in Nijmegen breakage syndrome (NBS; MIM 251260)-were isolated by TAR cloning and loaded into the unique loxP site of the alphoid tetO -HAC in CHO cells. HAC transfer into human cells deficient in NBS1 and VHL reveals that both genes are expressed normally and complement the defective endogenous alleles.
Results
Isolation of Genomic Regions Containing NBS1 and VHL Genes from Human Genome by TAR Cloning. The TAR cloning scheme for isolating the NBS1 and VHL genes is shown in Fig. 1A . For cloning purposes, TAR vectors were designed containing short targeting hooks specific to 5′ and 3′ sequence ends of the genes (SI Materials and Methods). Fig. 1 F and H) and did not reveal any structural rearrangements. Analysis of the NBS1 genomic segments is shown in Fig. S1 . (23) by Southern blot hybridization. To insert genomic copies of the NBS1 and VHL genes into the alphoid tetO -HAC, the appropriate BAC constructs and a Cre-recombinase expression vector were cotransfected into hprt-minus CHO cells carrying the HAC and HPRT-plus colonies were selected on HAT medium (Fig. 1C) . Insertion of genes into the HAC was confirmed by PCR by using specific primers (Table S1) (Fig.  2E) . Because antibodies against human pVHL produce a band with the mobility of hVHL on Western blots in naive CHO cell lysates, we used RT-PCR analysis to prove expression of the VHL gene. RT-PCR products of the predicted size were obtained (Fig. S4A) , and their identity was confirmed by sequencing.
Conversion of NBS1-and VHL-YACs into BACs with a LoxP Cassette for
Functional Complementation of Genetic Deficiency by Alphoid tetO -HAC/NBS1. To prove its use as a genetic complementation vector, the NBS1-containing HAC was transferred to NBS1-deficient GM07166 (657del5) human cells via microcell-mediated chromosome transfer (MMCT; Fig. 1D ). FISH analysis confirmed that alphoid tetO -HAC/NBS1 propagates autonomously without detectable integration into chromosomes (Fig. 3A) . Western blot analysis confirmed that this clone expresses pNBS1 (Fig. 3B) . To prove the functionality of the conditional kinetochore and confirm that pNBS1 is expressed from the HAC, we targeted the tTS transcriptional repressor to the HAC centromere in the alphoid tetO -HAC/NBS1-containing GM07166 cells (Fig. 1E) . This targeting results in a high frequency of HAC loss, as described previously (23, 24) (Fig. S5) . Based on FISH and Western blot analysis, cells that lost the HAC no longer expressed pNBS1 (Fig. 3B) .
We used physiological tests to prove that alphoid tetO -HAC/ NBS1 produces functional pNBS1. pNBS1 plays a critical role in damage responses to DNA double-strand breaks (DSBs). Within seconds of generation of DSBs, histone H2A.X molecules are phosphorylated by ATM and ATR on serine residues. The resulting γ-H2A.X spreads along megabase chromatin domains flanking the DSB site (reviewed in refs. 27, 28). pNBS1 then recruits the Mre11/Rad50/NBS1 complex to the break site. Although γ-H2A.X foci formed in NBS1-deficient GM07166 cells (Fig. 3 F-H) . In contrast, in GM07166 cells bearing alphoid tetO -HAC/NBS1, localization of NBS1 and MRE11 to damage-induced γ-H2A.X foci was observed (Fig. 3 F-H) . This colocalization was lost in GM07166 cells that had been "cured" of the HAC (Fig. 3 F-H) . As a control, we examined colocalization of γ-H2A.X and 53BP1 in the same cells. As shown by others, 53BP1 localization to damage foci is not affected by absence of pNBS1 (ref. 29 and references therein). Indeed, γ-H2A.X and 53BP1 irradiationinduced foci colocalized independently of the presence of functional pNBS1 in GM07166 cells (Fig. 3 F-H and Fig. S6) .
Analysis of three proteins-ATM, KAP1, and p53-that should be modified in response to irradiation revealed phosphorylation of the predicted amino acid residues in the analyzed cells (Fig. 3E) . We then analyzed kinetics of the disassembly of γ-H2A.X foci, which closely parallels the rate of DSB repair. The kinetics slows down in NBS1-deficient cells similar to that in cells deficient for ATM and 53BP1 (30) . GM07166 cells bearing alphoid tetO -HAC/NBS1 showed a more efficient disassembly of foci compared with cells without HAC after 24 h (Fig. 3 C and  D) . The dynamics of foci disassembly in the cells without and with the HAC was identical to that observed in cultured lymphocytes from patients with NBS and normal individuals, correspondingly (31 (RCCs) via MMCT, alphoid tetO -HAC/VHL propagated autonomously without integrating into host chromosomes (Fig. 4A) . These cells are VHL-negative as a result of a frameshift mutation in the coding region of the gene (311delG). Expression of VHL in 786-0 cells bearing alphoid tetO -HAC/VHL was confirmed by RT-PCR by using primers that specifically amplify the WT but not the mutant allele of VHL (Fig. S4B) . To prove that VHL is expressed from the HAC, a vector expressing a tTS fusion was introduced into cells to induce HAC loss (23, 24) . Several GFPnegative clones were selected. Based on FISH and RT-PCR analyses, these clones lost the VHL along with the HAC.
Several specific tests based on the known functions of pVHL were carried out to prove functional stable expression of pVHL from the HAC in recipient cells. A critical role of pVHL in down-regulation of HIF, CyclinD1, and Cdk1/CDC2 is well documented (32) (33) (34) (35) . pVHL has E3 ubiquitin ligase activity and targets α-subunits of HIF for rapid degradation by the proteasome under normoxia. Those subunits are stabilized by hypoxia (reviewed in ref. 36) . We compared the levels of HIF2α, CyclinD1, and CDC2 expression in VHL-deficient and isogenic cells containing alphoid tetO -HAC/VHL by Western blot analysis. As predicted, levels of HIF2α, CyclinD1, and CDC2 were significantly lower in cells carrying alphoid tetO -HAC/VHL (Fig.  4B) , suggesting that pVHL expressed from the HAC restores their normal down-regulation. Indeed, 786-0 cells cured of the alphoid tetO -HAC/VHL vector by centromere inactivation expressed the VHL-regulated proteins at their original elevated levels (Fig. 4B ). PGK1 and CA9 expression is regulated by hypoxia and more specifically by the HIF1-α isoform (PubMed ID no. 15964822). Because the 786-0 cell line lacks expression of HIF1-α, no reduction of CA9 and PGK1 was observed after induction of pVHL in 786-0 cells (Fig. 4B) .
Three additional tests confirmed the functional expression of pVHL in recipient alphoid tetO -HAC/VHL cells. In RCCs, hepatocyte growth factor (HGF) and FBS stimulate branching morphogenesis, cell invasiveness, and cell migration via a VHLdependent pathway (37, 38) . We therefore assessed those phenotypes in the VHL-deficient 786-0 RCC parental cell line and its isogenic derivative containing the alphoid tetO -HAC/VHL vector (Fig. 4 C-E) . Addition of exogenous HGF resulted in branching of VHL-deficient 786-0 cells in a growth factor-reduced Matrigel assay. In contrast, stable expression of pVHL from the alphoid tetO -HAC/VHL vector abrogated this morphologic response of 786-0 cells to HGF (Fig. 4D) . Similarly, the relatively high basal level of invasiveness of VHL-deficient 786-0 cells was markedly stimulated by addition of FBS. This response was dramatically suppressed in the isogenic 786-0 cell line containing the alphoid tetO -HAC/VHL vector (Fig. 4C) . Finally, migration of 786-0 cells with alphoid tetO -HAC/VHL was also reduced relative to the parental cell line (Fig. 4E) .
This battery of functional tests shows that the VHL gene expressed from the alphoid tetO -HAC/VHL produces a functional product that complements the VHL-deficiency in 786-0 cells.
Proximity of CENP-A Chromatin Is Compatible with Gene Expression.
During de novo HAC formation, input DNA is multimerized and then assembled into different types of chromatin, including arrays of CENP-A nucleosomes that are interspersed with those carrying different modifications of histone H3 (39) . To better understand the chromatin structure of regions flanking the NBS1 gene in the alphoid tetO HAC, alphoid tetO -HAC/NBS1 was transferred back to human HT1080 cells (Fig. S7) via MMCT. The alphoid tetO -HAC was generated in this host and its chromatin structure in those cells has been previously characterized (22) . After MMCT, two clones (NBS1 no. 3 and NBS1 no. 6) were selected (Fig. 5) . Immuno-FISH analysis confirmed the assembly of CENP-A centromeric chromatin on the HAC sequences (Fig. 5C ). ChIP analysis of these clones showed a chromatin pattern similar to that in the original alphoid tetO -HAC clone (AB2.2.18.21) (22) for CENP-A chromatin as well as H3K4me3 (a marker for transcriptionally active chromatin), H3K4me2 (a marker for open chromatin) and H3K9me3 (a marker for heterochromatin) on alphoid tetO DNA (Fig. 5 A and  B) . These results confirm that the alphoid tetO -HAC/NBS1 retained its kinetochore chromatin structure after several rounds of MMCT and gene insertion. ChIP analysis of regions flanking the NBS1 gene revealed a robust level of CENP-A chromatin enrichment at the 3′ end of NBS1 in clone NBS1 no. 3 and a lower, but still significant, enrichment in clone NBS1 no. 6 (Fig.  5A ). This indicates that the CENP-A chromatin domain extends to beyond the gene insertion site. CENP-A enrichment at the 3′ NBS1 sequence may be explained by the ability of CENP-A chromatin to spread onto noncentromeric DNA (16, 39, 40) . The observed stable gene expression in the HAC suggests that close proximity of the CENP-A domain does not prevent expression of Pol II-transcribed genes. 
Discussion
HACs represent a unique system for delivery and expression of full-length genes that has several advantages over currently used episomal virus-based vectors. Several groups have reported successful expression of full-length genes in HACs (9-11, 20, 21) . The most advanced top-down HAC vectors are truncated derivatives of chromosome 21. Determination of the structure of one such derivative, 5-Mb 21ΔpqHAC, opened the way for its use in clinical applications (18) . Recently, this HAC was successfully used for delivery and expression of several full-length human genes, including the 2-Mb Duchenne Muscular Dystrophy (DYS) gene (41) . However, a common limitation of all HACs constructed so far is the inability to induce HAC loss to enable transient gene expression or to have a negative control for phenotypic changes attributed to expression of the gene loaded into the HAC.
In our previous work, we developed a synthetic alphoid tetO -HAC with a conditional centromere that can be inactivated (22) . This HAC contains a unique loxP site that allows selection for gene loading (23) .
In the present study, we analyzed the capacity of the alphoid tetO -HAC to deliver genomic copies of average-size genes into human cells and complement genetic deficiencies. We found that the VHL and NBS1 genes obtained by TAR cloning can be efficiently and accurately introduced into the alphoid tetO -HAC, resulting in artificial chromosomes that can be propagated indefinitely in CHO cells. Because CHO cells exhibit a high efficiency of microcell formation, this enables transfer of the HAC to other cell types, including mouse ES cells, via MMCT (23, 42) .
The HACs were transferred into cell lines derived from patients with deficiencies in VHL or NBS1. Functional expression of pVHL and pNBS1 in recipient cells was demonstrated by a set of specific tests based on the known functions of proteins. Importantly, corresponding controls could be conducted following specific elimination (i.e., curing) of the HAC from the cells following targeted inactivation of the kinetochore. No significant changes in the level of expression of pNBS1 were detected for more than 3 mo following introduction of the alphoid tetO -HAC into patient-derived cell lines (Fig. S8 ). Although additional studies are needed to determine whether genes inserted into the alphoid tetO -HAC may eventually be subject to silencing, our results and those obtained with other HACs (21, 41) support the view that proximity to a functional kinetochore does not negatively affect gene expression. It is possible that, in the human genome, centromeric chromatin may be a privileged region for Pol II-transcribed genes, as previously shown for rice centromeres (43) and suggested by the resemblance of the centromeric chromatin profile to the downstream region of transcribed genes in human cells (39, 44) . Indirectly, this hypothesis is supported by our data on spreading of CENP-A chromatin to the 3′ end of NBS1 and transcriptional activity of genes in neocentromeres (reviewed in ref. 40) .
The alphoid tetO -HAC, with its conditional centromere, has significant advantages over other expression/cloning systems when transient expression of a gene of interest is needed. For example, generation of iPS cells requires only transient expression of specific cellular factors such as OCT4, SOX2, KLF4, cMYC, and LIN28 (45) . Therefore, the ability to eliminate the HAC along with any stem cell-inducing genes carried on it could provide a strategy to avoid insertional mutagenesis and cell transformation, complications that are frequently observed during cell reprogramming (46) . To adopt the alphoid tetO -HAC vector for such purpose, a HAC inactivation module consisting of the doxycycline-regulated tTS fusion is being incorporated into the HAC allowing induction of its loss by a simple addition of a ligand. For gene therapy, the HAC may be inserted into stem cells in the laboratory and then these stem cells may be introduced into the patient. It is worth noting that efficient formation and stable maintenance of HACs has been demonstrated in stem cells (47) .
To summarize, in this work, we demonstrate the utility of an alphoid tetO -HAC vector for delivery of full-length genes and correction of genetic deficiencies in human cells. We also demonstrate the benefit of coupling the TAR gene cloning technology, which provides an effectively unlimited resource of fulllength human genes, with the tetO-loxP-HAC gene delivery and expression system. Because the structure of the alphoid tetO -HAC 
